BAC2021 banner thin Veertly(3).png

October 1 in Heidelberg & digital

The ways in which we treat diseases are becoming more and more innovative, with the biotech industry demonstrating its full potential in the development of new ways to treat patients.

Our industry is constantly inventing, validating, and developing new drug modalities such as antibody-drug conjugates, RNA therapeutics, targeted degradation, gene editing, oligonucleotides and various combinations of these and other tools to address pathophysiological conditions.

Collaboration among industry, academia, regulatory, clinician and patient communities, as well as ad hoc funding and investment frameworks are essential to bring these solutions to the patients.

This year Annual Conference presents some of these biotechnology-driven new therapeutical approaches and partnership models for successful drug development.

Registration opens soon!

AGENDA (9:00 - 17:00)


mRNA-based cancer therapies (tba)


Dirk Grimm, Heidelberg University Hospital & Aavigen GmbH 

Christiane Kofink, Boehringer Ingelheim

Ivan Đikić, University of Frankfurt

Claus Kremoser, WMT - We Make Cancer Therapeutics

Michael Zimmermann, EMBL


2-3 parallel workshops "from members to members"


Florian Vogel, MYR and Stephan Urban, University Hospital Heidelberg

Speed-networking & Happy Hour

The conference is an event organised for BioRN members, associated and friends.

Since 2009, each year the BioRN Annual Conference has been a valuable source of top information, lively discussions and networking opportunities with international experts from different fields of the life sciences.



Key Public Partner